Vitamin d and Hypertonia - a phase IV clinical study of FDA data

Summary:

Hypertonia is reported as a side effect among people who take Vitamin d (ergocalciferol), especially for people who are female, 40-49 old, have been taking the drug for 2 - 5 years also take Gilenya, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Hypertonia when taking Vitamin d. It is created by eHealthMe based on reports of 282,675 people who have side effects when taking Vitamin d from the FDA, and is updated regularly.

What is Vitamin d?

Vitamin d has active ingredients of ergocalciferol. It is often used in low vitamin d. eHealthMe is studying from 294,095 Vitamin d users. Check the latest studies of Vitamin d.

What is Hypertonia?

Hypertonia (abnormal increase in muscle tension and a reduced ability of a muscle to stretch) is found to be associated with 490 drugs and 695 conditions by eHealthMe. Check the latest studies of Hypertonia.

On Aug, 06, 2026

282,675 people reported to have side effects when taking Vitamin d.
Among them, 61 people (0.02%) have Hypertonia.

Among these 61 people:

How long have people been on Vitamin d when they have Hypertonia? *

What is the gender of people who have Hypertonia when taking Vitamin d? *

female: 73.77 %
male: 26.23 %

What is the age of people who have Hypertonia when taking Vitamin d? *

What are other drugs people take besides Vitamin d? *

What are other side effects people have besides Hypertonia? *

Weakness: 37 people, 60.66%
Fatigue (feeling of tiredness): 33 people, 54.10%
Gait Disturbance: 31 people, 50.82%
Memory Loss: 27 people, 44.26%
Speech Impairment (Adult) (inability to speak (adult)): 23 people, 37.70%
Balance Disorder: 22 people, 36.07%
Back Pain: 21 people, 34.43%
Fall: 21 people, 34.43%
Lymphocyte Count Decreased: 20 people, 32.79%
Acute Upper Airway Obstruction (blockage occurs in the upper airway): 19 people, 31.15%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 17 people, 27.87%
Secondary Progressive Multiple Sclerosis (a stage of ms which comes after relapsing remitting ms in many cases): 16 people, 26.23%
Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 11 people, 18.03%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 10 people, 16.39%
Gait Disturbance: 8 people, 13.11%
High Blood Pressure: 5 people, 8.20%
Dyslipidaemia (abnormal amount of lipids): 4 people, 6.56%
Fatigue (feeling of tiredness): 4 people, 6.56%
Pain: 4 people, 6.56%
Major Depression (a mood state that goes well beyond temporarily feeling sad or blue. it is a serious medical illness that affects one's thoughts, feelings): 3 people, 4.92%

* Approximation only. Some reports may have incomplete information.

Do you take Vitamin d and have Hypertonia?

- Check whether Hypertonia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Vitamin d:

Vitamin d (294,095 reports)

Hypertonia treatments and more:

Hypertonia (11,073 reports)

Browse all side effects of Vitamin d:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypertonia:

Hypertonia (490 drugs)

Browse all the conditions that are associated with Hypertonia:

Hypertonia (695 conditions)

Related publications that referenced our studies

Kapoor S, "Influence of Vitamin D Consumption and Levels on the Development of Psychiatric Disorders", Lee, Y. J., & Park, K. (2018). Secondary Raynaud’s Phenomenon and Skin Necrosis of Toes in the Paraplegic Patient with Hypertension.?Drug safety-case reports,?5(1), 7., 2014 Aug .
Kapoor S, "Influence of Vitamin D Consumption and Levels on the Development of Psychiatric Disorders", Lee, Y. J., & Park, K. (2018). Secondary Raynaud’s Phenomenon and Skin Necrosis of Toes in the Paraplegic Patient with Hypertension.?Drug safety-case reports,?5(1), 7., 2014 Aug .

How the study uses the data?

The study uses data from the FDA. It is based on ergocalciferol (the active ingredients of Vitamin d) and Vitamin d (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.